AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00235235
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m2 day 1 of every 21-day cycle
Trial: NCT00235235
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle
Trial: NCT00235235
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle
Trial: NCT01498458
Drug: Pazopanib plus capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive pazopanib tablets once daily at a dose according to the allocated dose level:~* dose level I: 400 mg~* dose level II: 600 mg~* dose level III: 800 mg~In addition patients receive capecitabine at the same oral dose for all dose levels with 1600 mg/m2 on days 1 to 14 every 3 weeks.~Treatment will be given until disease progression or unacceptable toxicity of the study drug, or withdrawal of consent of the patient.~Six patients will be recruited in each dose level. If less than 2 out of 6 patients experience a DLT within the first 2 cycles (weeks 1 to 6), the next dose level is started. Once the MTD is established, additional 6 patients will be included into this dose level to further characterise the safety of the dose regimen.~If it is reported, that two patients had a DLT, all patients are informed about it and the dose level immediately reduced by one dose level.
Trial: NCT01524224
Drug: LY2495655
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously
Trial: NCT01454609
Drug: 0.9% Normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT00296465
Drug: Pulsatile gonadotropin-releasing hormone (GnRH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
Trial: NCT00296465
Drug: Placebo Pulsatile GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
Trial: NCT04475588
Drug: Best supportive care (BSC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc
Trial: NCT02296411
Drug: CHF 5259 12.5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
Trial: NCT03662542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT00544258
Drug: PEP005
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01879410
Drug: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug is administered via NDPI as one inhalation once daily in the morning. NDPI has two strips, each containing 30 blisters of medication. The first strip has UMEC blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 62.5 mcg per blister and the second strip has VI blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 25 mcg per blister.
Trial: NCT01879410
Drug: FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains a single strip with 60 blisters of medication. The strip has 250 mcg of fluticasone propionate and 50 mcg of salmeterol per blister in the form of dry white powder.
Trial: NCT01879410
Drug: Placebo DISKUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains 1 strip with 60 blisters of placebo in the form of dry white powder.
Trial: NCT01879410
Drug: Placebo NDPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered via NDPI as one inhalation once daily in the morning. The inhaler contains 2 strips with 30 blisters of placebo per strip in the form of dry white powder.
Trial: NCT01991158
Drug: High dose of methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 3.0g/Kg, intravenous drip D1
Trial: NCT00581776
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by IV at 300 mg/m2, 6 doses spaced 12 hours apart on days 1-3 of each cycle, to start after completion of rituximab infusion
Trial: NCT00581776
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given as a continuous infusion, 50 mg/m2 over 48 hours days 1-2 of each cycle, to start after completion of rituximab infusion.
Trial: NCT02589782
Drug: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01147861
Drug: GSK256073
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg in the AM and 5mg in the PM
Trial: NCT01147861
Drug: GSK256073
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg in the AM
Trial: NCT01147861
Drug: GSK256073
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg in the AM
Trial: NCT01147861
Drug: GSK256073
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg in the AM and 25mg in the PM
Trial: NCT03500133
Drug: Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
Trial: NCT03500133
Drug: Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
Trial: NCT03500133
Drug: Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
Trial: NCT03500133
Drug: Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
Trial: NCT03500133
Drug: High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
Trial: NCT03500133
Drug: High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
Trial: NCT03500133
Drug: Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
Trial: NCT01865279
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single doses - 5 dose levels
Trial: NCT01066104
Drug: Xolair placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
Trial: NCT01865279
Drug: isophane human insulin
RxNorm normalized name: insulin isophane, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 0.4 IU/kg is administered to subjects with type 1 diabetes while a single dose of 0.6 IU/kg is administered to subjects with type 2 diabetes
Trial: NCT00636909
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: preparative cytoreduction
Trial: NCT00636909
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: immunosuppressive therapy
Trial: NCT00904670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day
Trial: NCT00904670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.
Trial: NCT03335904
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 50mg, BID
Trial: NCT03456349
Drug: HTL0018318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTL0018318
Trial: NCT03456349
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00075855
Drug: therapeutic testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01264692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsules matching ACT-280778
Trial: NCT01878578
Drug: phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hidantina® tablets containing 100 mg of phenytoin